• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Blinatumomab
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    Blincyto
    Amgen
    RX
    partial basket chart
    Blincyto

    Monoclonal Antibody. Blinatumomab 12.5 mcg/ml.
    VIAL (concentr. for sol. for infus.+ stabilizer sol. for infus.): 1×35mcg. Recommen. dly. dose is by pt. wt. Pts. greater than or equal to 45 kg receive a fixed-dose and for pts. less than 45 kg, dose is calc. using the pt’s. body surface area. (BSA).
    Recommen. dose for adult pts. at least 45 kg in wt. (fixed-dose): 1st Cycle: Start. dose Days 1–7: 9 mcg/d via cont. infus.
    Subseq. dose Days 8–28: 28 mcg/d via cont. infus. 2 week-tmt. free interval (Days 29-42).
    2nd cycle & subseq. cycles: (Days 1–28): 28 mcg/d via cont. infus.
    Pts. less than 45 kg (BSA-based dose):
    Days 1-7:
     5 mcg/m²/day via cont. infus. (do not exceed 9 mcg/day).
    Days 8-28: 15 mcg/m²/d via contin.  infus. (do not exceed 28 mcg/d).
    Subseq. Cycle Days 1-28: 15 mcg/m²/d via contin. infus. (do not exceed 28 mcg/d).
    MRD posit. B-precursor ALL for Philadelphia chrom. negat.: pts. may receive 1 cycle of induct. tmt. follow. by up to 3 addit. cycles of consol. tmt. A sgle. cycle of tmt. induct. or consol. is 28 d. (4 wks.) of contin. IV infus. follow. by a 14 d. (2 wk.) tmt. -free interv. (total 42 d.). The major. of pts. who resp. to blinatumomab achieve a resp. aft. 1 cycle. Therefore, the potent. benefit and risks assoc. with contin. ther. in pts. who do not show haematolog. and/or clinic. improv. after 1 tmt. cycle should be assessed by treat. phys. See lit.

    Monother. for tmt. of adlts. with CD19 posit. relapsed or refract. B prec. ac. lymphobl. leuk.(ALL). Pts. with Philadelphia chrom. posit. B-prec. ALL should have failed tmt. with at least 2 tyrosine kinase inhibitors (TKIs) and have no tmt. options.
    Monother. for tmt. of adlts. with Philadelphia chrom. negat. CD19 pos. B-prec. ALL in first or sec. compl. remission with min. res. dis. (MRD) greater than or equal to 0.1%.
    Monother. for tmt of ped. pts aged 1 year  min. with Philadelphia chrom. neg. CD19 pos. B-precursor ALL refract. or in relapse aft. receiving at least 2 prior ther. or in relapse aft. rec. prior allogen. hematop. stem cell transplant.
    Monother. for  tmt. of ped. pts. aged 1 year min. with high-risk first relapsed Philadelphia chrom. neg. CD19 posit. B-prec. ALL as part of the consolid. ther.
    Limit. of use:aft. fail. of 2 prev. tmts. and with no CNS involv.
    C/I: Hypersens. Breastfeeding.

    CLOSE